Modeling the IL-2-Teff-Treg system in Systemic Lupus Erythematosus patients: possible mechanism and treatment strategies

Xin Gao, Xiaolin Sun, Jing He, Fangting LibioRxiv 2020 · DOI

Abstract

Systemic lupus erythematosus (SLE) is a non-organ specific autoimmune disease with a complex pathogenesis. To elucidate the underlying mechanisms, we constructed a mathematical model depicting the interactions among CD4+ regulatory T cells (Treg), CD4+ effector T cells (Teff), and Interleukin-2 (IL-2) in SLE patients. Our analysis suggests that SLE pathogenesis may be driven by a "forward shift" in the activation and deactivation thresholds of Teff cells compared to healthy controls. Simulations identify a specific therapeutic window for exogenous IL-2 treatment, highlighting the necessity for precise dosing. Furthermore, we evaluated three dosing strategies, revealing that specific regimens can maximize Treg expansion while minimizing the inflammatory risks associated with high-dose IL-2. This work provides a quantitative framework for advancing precision medicine in autoimmune disorders.

Introduction

Systemic Lupus Erythematosus (SLE) represents a significant challenge in immunology, characterized by a breakdown in self-tolerance and chronic systemic inflammation. Central to this pathology is the imbalance between Effector T cells (Teff), which orchestrate inflammatory responses, and Regulatory T cells (Treg), which maintain immune homeostasis. Interleukin-2 (IL-2) serves as a critical common resource for both populations. While low-dose IL-2 therapy has emerged as a promising strategy to selectively expand Tregs, the narrow margin between therapeutic benefit and disease exacerbation necessitates a rigorous quantitative understanding of the system's dynamics.

Mathematical Modeling Framework

To capture the complexity of the immune response, a dual-modeling approach was employed. The primary model consists of a system of 15 Ordinary Differential Equations (ODEs) that integrate intracellular signaling pathways—including STAT5, NFAT, and Blimp1—with population-level dynamics. This model explicitly accounts for the competition between Teff and Treg cells for IL-2 and the subsequent inhibitory feedback loops.

To facilitate stability analysis, the complex system was reduced to a simplified two-variable motif using a modified Lotka-Volterra framework. This reduction allowed for the mapping of nullclines and the identification of stable fixed points, representing the "healthy" and "diseased" states of the immune system. Sensitivity analysis was performed using the Sobol method to identify the biological parameters most influential in determining the therapeutic window.

Pathogenesis: The "Forward Shift" and Bistability

A key finding of the model is the identification of a "forward shift" in the activation thresholds of Teff cells in SLE patients. In healthy individuals, the immune system requires a specific level of antigenic stimulation to trigger an inflammatory response. In SLE patients, this activation point is shifted, meaning the system is hyper-sensitive and easily triggered by lower levels of antigen compared to healthy controls.

Furthermore, the model demonstrates that the immune system exhibits bistability. Once the system crosses the threshold into an over-activated state, it becomes trapped in a "diseased" stable fixed point. Returning to a healthy state is not merely a matter of removing the trigger but requires a precise intervention to push the system back across the stability threshold.

The Therapeutic Window for IL-2

The simulation results highlight a critical therapeutic window for exogenous IL-2 administration. Because Tregs express a higher density of IL-2 receptors (high-affinity IL-2Rα) compared to resting Teffs, they possess a competitive advantage at low cytokine concentrations. The model identifies a specific concentration (approximately 0.015 nM) where Treg function is maximized without inadvertently activating the Teff population.

However, this window is fragile. Sensitivity analysis revealed that parameters related to Treg-mediated inhibition and kill rates (Parameters 41 and 42) are the primary determinants of the window's width. This suggests that the efficacy of IL-2 therapy is highly dependent on the individual patient's underlying immune parameters.

Dosing Strategies and Clinical Implications

The study evaluated various dosing regimens to optimize the therapeutic effect:

  1. Low-Dose Periodic Administration: This was found to be the most effective strategy for maintaining Treg superiority, though it is highly sensitive to the "off-time" between doses.
  2. High-Dose Risks: High doses of IL-2 "shield" the therapeutic window, bypassing the selective expansion of Tregs and leading directly to Teff over-proliferation and clinical flares.
  3. Density-Dependent Responses: The model also accounts for cell density variations between peripheral blood and lymph nodes. High-density environments respond more rapidly to antigens, explaining the localized nature of early immune responses.

Conclusion

This mathematical framework provides a robust tool for understanding the IL-2-Teff-Treg axis in SLE. By identifying the "forward shift" in Teff activation and defining the therapeutic window for IL-2, this research paves the way for more personalized treatment protocols. Future work will focus on incorporating additional cell types, such as dendritic cells, and addressing the spatial heterogeneity of the immune system to further refine these predictive models for clinical use.

Summary updated

Abstract

Summary Systemic lupus erythematosus (SLE) is a non-organ specific autoimmune disease, which the pathogenesis of development is still unclear. For revealing the underlying mechanism, we construct a mathematical model depicting the interactions among CD4 + regulatory T cells (Treg cells), CD4 + effect T cells (Teff cells) and IL-2 in SLE patients to simulate and reproduce the development of SLE. Through our analysis, one possible pathogenesis is that the activation point and deactivation point of Teff in SLE patients produced a forward shift compared to the normal Teff. According to our simulation, a therapeutic window existed in the treatment of lupus with exogenous IL-2, which means there is a strict limit to the dose of IL-2 in clinic. Finally, we study three different dosing strategies and reveal that specific dosing regimens can better exert the effects of IL-2 and relieve the possible side effect of high dose IL-2. It is possible to promote the study of autoimmune diseases through our efforts and assist the development of precision medical treatment.
BibTeX
@misc{gao2020modeling,
  author = {Xin Gao and Xiaolin Sun and Jing He and Fangting Li},
  title = {{Modeling the IL-2-Teff-Treg system in Systemic Lupus Erythematosus patients: possible mechanism and treatment strategies}},
  year = {2020},
  doi = {10.1101/2020.05.14.095513},
  howpublished = {bioRxiv},
}
Figure